<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885441</url>
  </required_header>
  <id_info>
    <org_study_id>22/52/1663</org_study_id>
    <nct_id>NCT02885441</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Pancreatitis With Ketorolac</brief_title>
  <official_title>Treatment of Acute Pancreatitis With Ketorolac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ilam University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ilam University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute pancreatitis will be randomly assigned in either study group to receive
      oral Ketorolac or control group (double blind study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute pancreatitis will be randomly assigned in either study group or control
      group (double blind study).

        -  The study group will receive oral Ketorolac

        -  The control group will receive a placebo

      Ketorolac is administrated three times daily by mouth starting from the time of admission for
      the first three days of hospitalization (72 hours).

      Hs-CRP will be measured in admission in addition to standard laboratory tests.It will be done
      every day for up to 5 days, after the administration of study drug or till the time of
      discharge whichever occurs earlier. Patients will follow up for organ failure involvement and
      duration of hospitalization. The study will continue to gather clinical follow up information
      up to four months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP)</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Organ Failure During Hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of beginning and tolerance to nutrition</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tab Ketorolac,10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tab placebo,10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Tab Ketorolac, 10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tab Placebo, 10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Predicted Severe Acute Pancreatitis

          2. Enrollment within 72 hours of diagnosis

          3. Obtaining informed consent

          4. Age &gt;18 years

        Exclusion Criteria:

          1. Heart disease, Hypertension

          2. Hemorrhagic diathesis, Incomplete hemostasis, High risk of bleeding

          3. Lactating women

          4. Pregnancy

          5. Advanced renal disease

          6. Hypersensitivity to ketorolac, aspirin, other NSAIDs

          7. Concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline

          8. Active or history of peptic ulcer disease

          9. Recent or history of GI bleeding or perforation

         10. Inflammatory bowel disease

         11. Severe hepatic impairment or active hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaahin Shahbazi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaahin Shahbazi, MD</last_name>
    <phone>+98(0)9122048023</phone>
    <email>mdkabe@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
    <phone>+98(0)9122138186</phone>
    <email>nutritiondata@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ilam University of Medical Scienvc</name>
      <address>
        <city>Ilam</city>
        <zip>6939177143</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaahin Shahbazi, MD</last_name>
      <phone>98(9)9122048023</phone>
      <email>mdkabe@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
      <phone>98(9)9122138186</phone>
      <email>nutritiondata@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ilam University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

